The AIM-listed company will also host its third Scientific Advisory Meeting with high profile US key opinion leaders in the field of erectile dysfunction (ED).
Next Thursday, Futura clinical development director Tim Holland will present a poster entitled "Ultrasound Doppler Measurements of Penile Blood Flow as a Predictor of Clinical Efficacy" as part of the "Erectile Dysfunction Medical/Surgical Moderated Posters" session.
Futura will also present cumulative safety data for MED2005, its fast-acting topical gel for the treatment of erectile dysfunction, in an oral presentation entitled "Establishing the safety profile in sexual partners of a new topical nitroglycerin gel for the treatment of erectile dysfunction".
"We are very pleased to share these findings on our lead programme MED2005 with the medical community at this prestigious meeting ahead of our Phase 3 data readout at the end of the year," said Futura CEO James Barder.
MED2005 has so far indicated that it is safe and gets working in 5-10 minutes with a favourable side-effects compared to other ED products on the market.